远大医药尾盘涨超7% 今日盘后将发中期业绩机构看好公司进入加速发展阶段

智通财经08-19

远大医药(00512)股价绩前抢跑，尾盘涨幅扩大逾7%。截至发稿，涨6.92%，报8.96港元，成交额2.83亿港元。消息面上，远大医药拟于8月19日举行董事会会议批准中期业绩。公司近期宣布，公司全线放射性产品钇[90Y]微球注射液正式获得美国FDA批准新增适应症，用于治疗不可切除肝细胞癌(HCC)，成为全球首个且唯一获FDA批准用于不可切除肝细胞癌和结直肠癌肝转移双重适应症的选择性内放射治疗产品...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2560197036?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-19 15:57","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2560197036","market":"us","top_or_hot":-1,"title":"远大医药尾盘涨超7% 今日盘后将发中期业绩 机构看好公司进入加速发展阶段","media":"智通财经","content":"<div>\n<p>远大医药(00512)股价绩前抢跑，尾盘涨幅扩大逾7%。截至发稿，涨6.92%，报8.96港元，成交额2.83亿港元。消息面上，远大医药拟于8月19日举行董事会会议批准中期业绩。公司近期宣布，公司全线放射性产品钇[90Y]微球注射液正式获得美国FDA批准新增适应症，用于治疗不可切除肝细胞癌(HCC)，成为全球首个且唯一获FDA批准用于不可切除肝细胞癌和结直肠癌肝转移双重适应症的选择性内放射治疗产品...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819161230a6eea6a6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>远大医药尾盘涨超7% 今日盘后将发中期业绩 机构看好公司进入加速发展阶段</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n远大医药尾盘涨超7% 今日盘后将发中期业绩 机构看好公司进入加速发展阶段\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-19 15:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819161230a6eea6a6&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>远大医药(00512)股价绩前抢跑，尾盘涨幅扩大逾7%。截至发稿，涨6.92%，报8.96港元，成交额2.83亿港元。消息面上，远大医药拟于8月19日举行董事会会议批准中期业绩。公司近期宣布，公司全线放射性产品钇[90Y]微球注射液正式获得美国FDA批准新增适应症，用于治疗不可切除肝细胞癌(HCC)，成为全球首个且唯一获FDA批准用于不可切除肝细胞癌和结直肠癌肝转移双重适应症的选择性内放射治疗产品...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819161230a6eea6a6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4006","symbol_name":"钢铁","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819161230a6eea6a6&s=b","article_id":"2560197036","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819161230a6eea6a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2560197036","pubTimestamp":1755590273,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"远大医药股价绩前抢跑，尾盘涨幅扩大逾7%。消息面上，远大医药拟于8月19日举行董事会会议批准中期业绩。天风证券此前指出，公司在核药板块已建立完整产业链，核心产品易甘泰钇[90Y]微球注射液用于治疗不可切除HCC和结直肠癌肝转移患者的核素介入治疗手段，产品2022年于国内获批上市后快速放量，截至2024年末，已累计治疗近2000例患者，2024年实现近5亿元销售收入。该行看好公司进入加速发展阶段。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4006":"钢铁","HCC":"Warrior Met Coal LLC"},"translate_title":"Grand Pharmaceutical rose more than 7% in late trading and will issue interim results after hours today. Institutions are optimistic that the company has entered a stage of accelerated development","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCC":1},"content_text":"远大医药(00512)股价绩前抢跑，尾盘涨幅扩大逾7%。截至发稿，涨6.92%，报8.96港元，成交额2.83亿港元。消息面上，远大医药拟于8月19日举行董事会会议批准中期业绩。公司近期宣布，公司全线放射性产品钇[90Y]微球注射液正式获得美国FDA批准新增适应症，用于治疗不可切除肝细胞癌(HCC)，成为全球首个且唯一获FDA批准用于不可切除肝细胞癌和结直肠癌肝转移双重适应症的选择性内放射治疗产品。天风证券此前指出，公司在核药板块已建立完整产业链，核心产品易甘泰钇[90Y]微球注射液用于治疗不可切除HCC和结直肠癌肝转移患者的核素介入治疗手段，产品2022年于国内获批上市后快速放量，截至2024年末，已累计治疗近2000例患者，2024年实现近5亿元销售收入。公司致力于构建肿瘤介入治疗+RDC平台实现核药板块全面布局，多款核药积极推进临床研发。该行看好公司进入加速发展阶段。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2560197036","isCrawlerRequest":true}

远大医药尾盘涨超7% 今日盘后将发中期业绩 机构看好公司进入加速发展阶段

精彩评论

远大医药尾盘涨超7% 今日盘后将发中期业绩机构看好公司进入加速发展阶段